Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies
Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies
复制标题
DOI：
10.1016/s0165-5728(01)00261-2
复制
发表时间：
2001-04-02
影响因子：
3.3
通讯作者：
Cosi, V
中科院分区：
文献类型：
--
作者：
Franciotta, D;Martino, G;Cosi, V
单核细胞趋化蛋白(MCP)-1和γ -干扰素诱导蛋白(IP)-10这两种趋化因子被认为与多发性硬化症（MS）的发病机制有关。我们测量了38例急性MS患者和25例稳定MS患者以及40例对照者血清和脑脊液中MCP-1和IP-10的水平。后者包括其他炎症性神经系统疾病（OIND）或非炎症性神经系统疾病患者和健康对照。脑脊液MCP-1水平高于所有研究患者和健康对照者血清中MCP-1水平。急性MS患者CSF MCP-1水平明显降低[468 +/- (S.E.M.)]。稳定质谱（857 +/- 104 pg/ml）高于稳定质谱（18 pg/ml）。急性多发性硬化症（血清331 +/- 66 pg/ml；脑脊液118 +/- 16 pg/ml）血清和脑脊液IP-10水平明显高于稳定多发性硬化症（血清69 +/- 7 pg/ml；脑脊液25 +/- 2 pg/ml）。在OIND患者中，伴有hiv -1相关痴呆的患者血清和脑脊液中MCP-1和IP-10水平均较高。脑炎患者血清和脑脊液中IP-10水平升高，脑脊液单核细胞增多。我们还评估了6-甲基强的松龙或ifn - β 1a治疗对循环MCP-1和IP-10水平的影响。治疗后MCP-1和IP-10水平与基线值没有显著差异。我们的研究结果表明：(a) MCP-1可以在大脑内组成性地产生；(b)急性多发性硬化症患者的MCP-1和IP-10 CSF水平与稳定型多发性硬化症患者有显著差异，且这些差异是相反的；(c)目前的多发性硬化症治疗不改变循环中MCP-1和IP-10的水平。(C) 2001 Elsevier Science B.V.版权所有
The two chemokines, monocyte chemoattractant protein (MCP)-1 and gamma -interferon inducible protein (IP)-10, are thought to be involved in the pathogenesis of multiple sclerosis (MS). We measured MCP-1 and IP-10 levels in serum and CSF samples from 38 acute and 25 stable MS patients and from 40 controls. The latter consisted in patients with other inflammatory neurological diseases (OIND) or with non-inflammatory neurological diseases, and healthy controls. CSF MCP-1 levels exceeded those found in serum in all the patients studied as well as in healthy controls. CSF MCP-1 levels were significantly Lower in acute MS [468 +/- (S.E.M.) 18 pg/ml] than in stable MS (857 +/- 104 pg/ml). When detectable, serum and CSF IP-10 levels were significantly higher in acute MS (serum 331 +/- 66 pg/ml; CSF 118 +/- 16 pg/ml) than in stable MS (serum 69 +/- 7 pg/ml; CSF 25 +/- 2 pg/ml). Among OIND patients, those with HIV-1-associated dementia showed high serum and CSF levels of both MCP-1 and IP-10. Those with encephalitis showed high serum and CSF levels of IP-10 and CSF mononuclear pleiocytosis. We also evaluated the effects of 6-methylprednisolone or IFN-beta 1a therapy on circulating MCP-1 and IP-10 levels. Neither MCP-1 nor IP-10 post-therapy levels varied significantly from baseline values. Our findings suggest that (a) MCP-1 could be constitutively produced within the brain; (b) MCP-1 and IP-10 CSF levels in acute MS vary significantly from those in stable MS. and these variations are inverse: and (c) current MS therapies do not modify circulating levels of MCP-1 and IP-10. (C) 2001 Elsevier Science B.V. All rights reserved.